Biotech News Pulse: 37 stocks worth noticing Po
Post# of 98007
Posted On: 01/11/2013 9:39:22 PM
Biotech News Pulse: 37 stocks worth noticing
Posted by Gary Demarzo on Jan 11, 2013
Pacific Biosciences of California (NASDAQ ACB) was the most gaining stock among biotech companies on Thursday after news hit the market that the U.S. Food and Drug Administration, Aligent Technologies and UC Davis will conduct a major study using the company’s Single Molecule, Real-Time (SMRT) technology.
Pain Therapeutics, Inc. (NASDAQ TIE) skyrocketed 10.9%, scoring second gain in a row.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) added 6% after CEO, John Crowley, presentation at the 31st Annual J.P. Morgan Healthcare Conference Call January 9, 2013 6:00 PM ET.
Repros Therapeutics Inc. (NASDAQ:RPRX) jumped to new 1-year high on promising results from Proellex study.
Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) rallied after its corporate presentation at the Biotech Showcase at 11:30 AM PT (2:30 PM ET) on Tuesday, January 8.
Peregrine Pharmaceuticals (NASDAQ PHM) surged as was gaining investors confidence after the data problems were limited to the 1 mg bavituximab arm.
Cell Therapeutics Inc (NASDAQ:CTIC) increased in price on news that the company begun enrolling patients in a phase III clinical trial, known as PERSIST-1.
Celgene Corporation (NASDAQ:CELG) was on new high yesterday, extending 7-day winning streak as the cancer drug maker issued strong guidance and positive trial results for one of its most important experimental drugs.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) continued to gain on positive data from Phase I hyperphosphatemia trial.
Novavax, Inc. (NASDAQ:NVAX) advanced as Wyatt Investment Research was of a view that the company may be on the verge of a massive spike due to a harsher-than-expected flu season.
Illumina, Inc. (NASDAQ:ILMN) increased 2% as preliminary Q4 revenues beat estimates and earnings were expected to meet guidance.
Geron Corporation (NASDAQ:GERN) traded up after issuing an update on Stem Cell Assets.
Celsion Corporation (NASDAQ:CLSN), YM BioSciences Inc. (USA) (NYSEAMEX:YMI), Gilead Sciences, Inc. (NASDAQ:GILD) and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) all ended in green.
Surprisingly, Rexahn Pharmaceuticals, Inc. (NYSEAMEX:RNN), PharmAthene, Inc. (NYSEAMEX IP), Hemispherx BioPharma, Inc (NYSEAMEX:HEB) and CEL-SCI Corporation (NYSEAMEX:CVM) all closed with no change.
On the flip side, Cytokinetics, Inc. (NASDAQ:CYTK) turned red to emerge as the biggest loser in the biotechnology industry.
Sequenom, Inc. (NASDAQ:SQNM) was the second biggest loser on a day when its Chairman and CEO Harry F. Hixson, Jr., Ph.D, and Ronald M. Lindsay, Ph.D., Director and EVP of Strategic Planning were set to make the presentation at the J.P. Morgan Healthcare Conference.
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) trimmed Wednesday’s rally, retreating 7.10% on Thursday after a 19.3 percent gain over the last two sessions.
Dendreon Corporation (NASDAQ NDN) declined on rumor that the European Approval is delayed.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR), Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) and Sarepta Therapeutics Inc (NASDAQ:SRPT) all were in red after the presentation at the J.P. Morgan Healthcare Conference.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ,VIVUS, Inc. (NASDAQ:VVUS), Galena Biopharma Inc (NASDAQ:GALE) all fell between 2.5% to 3.3%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Oncothyreon Inc (USA) (NASDAQ:ONTY), Amgen, Inc. (NASDAQ:AMGN), MannKind Corporation (NASDAQ:MNKD), PDL BioPharma Inc. (NASDAQ DLI) and Biogen Idec Inc. (NASDAQ:BIIB) all closed in a range of 0% to 2.5%.
Posted by Gary Demarzo on Jan 11, 2013
Pacific Biosciences of California (NASDAQ ACB) was the most gaining stock among biotech companies on Thursday after news hit the market that the U.S. Food and Drug Administration, Aligent Technologies and UC Davis will conduct a major study using the company’s Single Molecule, Real-Time (SMRT) technology.
Pain Therapeutics, Inc. (NASDAQ TIE) skyrocketed 10.9%, scoring second gain in a row.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) added 6% after CEO, John Crowley, presentation at the 31st Annual J.P. Morgan Healthcare Conference Call January 9, 2013 6:00 PM ET.
Repros Therapeutics Inc. (NASDAQ:RPRX) jumped to new 1-year high on promising results from Proellex study.
Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) rallied after its corporate presentation at the Biotech Showcase at 11:30 AM PT (2:30 PM ET) on Tuesday, January 8.
Peregrine Pharmaceuticals (NASDAQ PHM) surged as was gaining investors confidence after the data problems were limited to the 1 mg bavituximab arm.
Cell Therapeutics Inc (NASDAQ:CTIC) increased in price on news that the company begun enrolling patients in a phase III clinical trial, known as PERSIST-1.
Celgene Corporation (NASDAQ:CELG) was on new high yesterday, extending 7-day winning streak as the cancer drug maker issued strong guidance and positive trial results for one of its most important experimental drugs.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) continued to gain on positive data from Phase I hyperphosphatemia trial.
Novavax, Inc. (NASDAQ:NVAX) advanced as Wyatt Investment Research was of a view that the company may be on the verge of a massive spike due to a harsher-than-expected flu season.
Illumina, Inc. (NASDAQ:ILMN) increased 2% as preliminary Q4 revenues beat estimates and earnings were expected to meet guidance.
Geron Corporation (NASDAQ:GERN) traded up after issuing an update on Stem Cell Assets.
Celsion Corporation (NASDAQ:CLSN), YM BioSciences Inc. (USA) (NYSEAMEX:YMI), Gilead Sciences, Inc. (NASDAQ:GILD) and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) all ended in green.
Surprisingly, Rexahn Pharmaceuticals, Inc. (NYSEAMEX:RNN), PharmAthene, Inc. (NYSEAMEX IP), Hemispherx BioPharma, Inc (NYSEAMEX:HEB) and CEL-SCI Corporation (NYSEAMEX:CVM) all closed with no change.
On the flip side, Cytokinetics, Inc. (NASDAQ:CYTK) turned red to emerge as the biggest loser in the biotechnology industry.
Sequenom, Inc. (NASDAQ:SQNM) was the second biggest loser on a day when its Chairman and CEO Harry F. Hixson, Jr., Ph.D, and Ronald M. Lindsay, Ph.D., Director and EVP of Strategic Planning were set to make the presentation at the J.P. Morgan Healthcare Conference.
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) trimmed Wednesday’s rally, retreating 7.10% on Thursday after a 19.3 percent gain over the last two sessions.
Dendreon Corporation (NASDAQ NDN) declined on rumor that the European Approval is delayed.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR), Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) and Sarepta Therapeutics Inc (NASDAQ:SRPT) all were in red after the presentation at the J.P. Morgan Healthcare Conference.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ,VIVUS, Inc. (NASDAQ:VVUS), Galena Biopharma Inc (NASDAQ:GALE) all fell between 2.5% to 3.3%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Oncothyreon Inc (USA) (NASDAQ:ONTY), Amgen, Inc. (NASDAQ:AMGN), MannKind Corporation (NASDAQ:MNKD), PDL BioPharma Inc. (NASDAQ DLI) and Biogen Idec Inc. (NASDAQ:BIIB) all closed in a range of 0% to 2.5%.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼